Human Antimicrobial Peptides' Antifungal Activity Against Aspergillus Fumigatus

Overview

Journal Eur J Clin Microbiol Infect Dis

Publisher Springer

Specialties Infectious Diseases
Microbiology

Date 2008 Jun 21

PMID 18566844

Citations 19

Authors

A Lupetti

J T van Dissel

C P J M Brouwer

P H Nibbering

Affiliations

Soon will be listed here.

Abstract

In light of the need for new antifungals, we compared the in vitro antifungal activity of two peptides derived from human lactoferrin (hLF), i.e., hLF(1-11) and hLF(21-31), two analogs of histatin 5, further referred to as dhvar4 and dhvar5, and two ubiquicidin (UBI)-derived peptides, i.e., UBI 18-35 and UBI 29-41, with that of amphotericin B against Aspergillus fumigatus hyphae using the MTT assay. The results revealed a dose-dependent antifungal activity for all peptides, with dhvar5 being the most potent peptide. In addition, hLF(1-11), dhvar5, and UBI 18-35 were effective against A. fumigatus conidia. Furthermore, hLF(1-11) did not lyze human erythrocytes, whereas dhvar5 (>or=16 microM) and UBI 18-35 (>or=20 microM) were hemolytic. Based on these in vitro results and their effectiveness against infections in mice, we concluded that hLF(1-11) and dhvar5 are promising candidates for the development of new agents against A. fumigatus infections.

Citing Articles

Humoral Immunity Against Aspergillus fumigatus.

Delliere S, Aimanianda V Mycopathologia. 2023; 188(5):603-621.

PMID: 37289362 PMC: 10249576. DOI: 10.1007/s11046-023-00742-0.

Specific Focus on Antifungal Peptides against Azole Resistant : Current Status, Challenges, and Future Perspectives.

Pimienta D, Cruz Mosquera F, Palacios Velasco I, Giraldo Rodas M, Onate-Garzon J, Liscano Y J Fungi (Basel). 2023; 9(1).

PMID: 36675863 PMC: 9864941. DOI: 10.3390/jof9010042.

Nlrx1-Regulated Defense and Metabolic Responses to Are Morphotype and Cell Type Specific.

Kastelberg B, Ayubi T, Tubau-Juni N, Leber A, Hontecillas R, Bassaganya-Riera J Front Immunol. 2021; 12:749504.

PMID: 34790195 PMC: 8591139. DOI: 10.3389/fimmu.2021.749504.

A Synergic Potential of Antimicrobial Peptides against pv. .

Mariz-Ponte N, Regalado L, Gimranov E, Tassi N, Moura L, Gomes P Molecules. 2021; 26(5).

PMID: 33800273 PMC: 7962642. DOI: 10.3390/molecules26051461.

Host defence peptides identified in human apolipoprotein B as promising antifungal agents.

DellOlmo E, Gaglione R, Cesaro A, Cafaro V, Teertstra W, de Cock H Appl Microbiol Biotechnol. 2021; 105(5):1953-1964.

PMID: 33576886 PMC: 7907042. DOI: 10.1007/s00253-021-11114-3.

References

Thevissen K, Kristensen H, Thomma B, Cammue B, Francois I . Therapeutic potential of antifungal plant and insect defensins. Drug Discov Today. 2007; 12(21-22):966-71. DOI: 10.1016/j.drudis.2007.07.016. View

Brouwer C, Bogaards S, Wulferink M, Velders M, Welling M . Synthetic peptides derived from human antimicrobial peptide ubiquicidin accumulate at sites of infections and eradicate (multi-drug resistant) Staphylococcus aureus in mice. Peptides. 2006; 27(11):2585-91. DOI: 10.1016/j.peptides.2006.05.022. View

Schippers E, Veer C, van Voorden S, Martina C, Huizinga T, le Cessie S . IL-10 and toll-like receptor-4 polymorphisms and the in vivo and ex vivo response to endotoxin. Cytokine. 2005; 29(5):215-28. DOI: 10.1016/j.cyto.2004.12.005. View

Lupetti A, Brouwer C, Bogaards S, Welling M, de Heer E, Campa M . Human lactoferrin-derived peptide's antifungal activities against disseminated Candida albicans infection. J Infect Dis. 2007; 196(9):1416-24. DOI: 10.1086/522427. View

Levitz S, DIAMOND R . A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT. J Infect Dis. 1985; 152(5):938-45. DOI: 10.1093/infdis/152.5.938. View

Herbrecht R, Denning D, Patterson T, Bennett J, Greene R, Oestmann J . Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347(6):408-15. DOI: 10.1056/NEJMoa020191. View

Helmerhorst E, Reijnders I, Vant Hof W, Veerman E, Amerongen A . Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. Antimicrob Agents Chemother. 1999; 43(3):702-4. PMC: 89188. DOI: 10.1128/AAC.43.3.702. View

Lin S, Schranz J, Teutsch S . Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001; 32(3):358-66. DOI: 10.1086/318483. View

Oppenheim F, Xu T, McMillian F, Levitz S, DIAMOND R, Offner G . Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol Chem. 1988; 263(16):7472-7. View

10.

Pfaller M, Grant C, Morthland V . Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans. J Clin Microbiol. 1994; 32(2):506-9. PMC: 263062. DOI: 10.1128/jcm.32.2.506-509.1994. View

11.

Hiemstra P, van den Barselaar M, Roest M, Nibbering P, Van Furth R . Ubiquicidin, a novel murine microbicidal protein present in the cytosolic fraction of macrophages. J Leukoc Biol. 1999; 66(3):423-8. DOI: 10.1002/jlb.66.3.423. View

12.

McNeil M, NASH S, Hajjeh R, Phelan M, Conn L, Plikaytis B . Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001; 33(5):641-7. DOI: 10.1086/322606. View

13.

Zasloff M . Antimicrobial peptides of multicellular organisms. Nature. 2002; 415(6870):389-95. DOI: 10.1038/415389a. View

14.

Lupetti A, Paulusma-Annema A, Welling M, Brouwer C, Senesi S, van Dissel J . Synergistic activity of the N-terminal peptide of human lactoferrin and fluconazole against Candida species. Antimicrob Agents Chemother. 2002; 47(1):262-7. PMC: 149030. DOI: 10.1128/AAC.47.1.262-267.2003. View

15.

Lupetti A, Paulusma-Annema A, Welling M, Senesi S, van Dissel J, Nibbering P . Candidacidal activities of human lactoferrin peptides derived from the N terminus. Antimicrob Agents Chemother. 2000; 44(12):3257-63. PMC: 90189. DOI: 10.1128/AAC.44.12.3257-3263.2000. View